Welcome to our dedicated page for Irhythm Technologies news (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on Irhythm Technologies stock.
iRhythm Technologies Inc (IRTC) delivers innovative digital cardiac monitoring solutions through its Zio System, combining wearable biosensors with AI-powered analytics. This page provides investors and healthcare professionals with direct access to official company announcements, including product updates, clinical research findings, and strategic developments shaping the future of ambulatory ECG diagnostics.
Discover timely updates on regulatory milestones, partnership agreements, and financial performance. Our curated collection ensures you stay informed about IRTC's advancements in extended cardiac monitoring technology and its growing role in preventive cardiology.
Explore press releases covering FDA clearances, peer-reviewed study validations, and operational expansions. All content is organized to highlight iRhythm's commitment to improving arrhythmia detection through cloud-connected devices and machine learning algorithms.
Bookmark this page for streamlined access to verified information about IRTC's market leadership in digital health solutions. Check back regularly to monitor how iRhythm continues to redefine patient care through clinically validated, data-driven insights.
iRhythm Technologies (NASDAQ:IRTC) announced the launch of the initial phase of its manufacturing automation plans, a significant milestone for the company. This phase involves implementing an advanced autohandler machine to automate the testing of printed circuit board assemblies (PCBAs) for the Zio monitor. This technology streamlines the testing process, enhancing operational efficiency and capacity. CEO Quentin Blackford highlighted the milestone's role in reducing costs and supporting global patient service expansion. The automation will also support future technology iterations, including next-gen mobile cardiac telemetry (MCT) products. iRhythm expects the complete manufacturing improvements to enable the production of up to 10 million units annually.
iRhythm Technologies (NASDAQ: IRTC), a leader in digital healthcare, announced its participation in the 2024 Truist Securities MedTech Conference. The company will engage in a fireside chat on June 18 at 9:20 a.m. ET. Stakeholders can access the live and archived webcast on iRhythm's investor website, providing insights into the company's strategies and innovations in disease detection and prevention.
iRhythm Technologies (NASDAQ: IRTC), a leading digital healthcare provider, will present at the William Blair 44th Annual Growth Stock Conference. The presentation is scheduled for June 5, 2024, at 11:20 a.m. Central Time. Attendees can access the live and archived webcast via the company's investor website.
iRhythm Technologies, a digital healthcare company, reported first quarter 2024 financial results with revenue of $131.9 million, an 18.4% increase from last year. Gross margin was 66.3% with cash reserves of $569.1 million. They increased their fiscal year 2024 revenue guidance to $578-$588 million. Operational highlights included over half a million registrations and collaborations to drive efficiencies. The CEO highlighted strong revenue growth, increased traction in primary care, and the potential of EKG data for clinical insights.
FAQ
What is the current stock price of Irhythm Technologies (IRTC)?
What is the market cap of Irhythm Technologies (IRTC)?
